Original Article

You have full text access to this OnlineOpen article

Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer

  1. Yoshihiko Segawa MD, PhD1,†,*,
  2. Katsuyuki Hotta MD, PhD2,
  3. Shigeki Umemura MD2,
  4. Yoshiro Fujiwara MD2,
  5. Tetsu Shinkai MD, PhD1,
  6. Hiroshi Ueoka MD, PhD3,
  7. Nagio Takigawa MD, PhD2,
  8. Masahiro Tabata MD, PhD2,
  9. Katsuyuki Kiura MD, PhD2,
  10. Mitsune Tanimoto MD, PhD2

Article first published online: 11 SEP 2006

DOI: 10.1002/cncr.22207

Issue

Cancer

Cancer

Volume 107, Issue 8, pages 1866–1872, 15 October 2006

Additional Information

How to Cite

Segawa, Y., Hotta, K., Umemura, S., Fujiwara, Y., Shinkai, T., Ueoka, H., Takigawa, N., Tabata, M., Kiura, K. and Tanimoto, M. (2006), Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer. Cancer, 107: 1866–1872. doi: 10.1002/cncr.22207

Author Information

  1. 1

    Department of Medicine and Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

  2. 2

    Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and Okayama University Hospital, Okayama, Japan

  3. 3

    Department of Medicine, National Hospital Organization Sanyo Hospital, Ube, Japan

  1. †

    Fax: (011) 81-89-999-1100.

*Department of Medicine and Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou Minami-Umemoto-cho, Matsuyama, Ehime 791-0288, Japan

Publication History

  1. Issue published online: 3 OCT 2006
  2. Article first published online: 11 SEP 2006
  3. Manuscript Accepted: 17 JUL 2006
  4. Manuscript Revised: 15 JUN 2006
  5. Manuscript Received: 21 APR 2006

Funded by

  • Ministry of Health, Labor, and Welfare of Japan. Grant Number: 15-15

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (115K)

REFERENCES

  • 1
    Smith W, Khuri FR. The care of the lung cancer patient in the 21st century: a new age. Semin Oncol. 2004; 31: 11–15.
  • 2
    Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995; 311: 899–909.
  • 3
    Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994; 12: 360–367.
  • 4
    Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol. 2004; 24: 64–69.
  • 5
    Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999; 17: 12–18.
  • 6
    Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000; 18: 623–631.
  • 7
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92–98.
  • 8
    Kubota K, Nishiwaki Y, Ohashi Y, et al. The four-arm cooperative study (FACS) in advanced non-small-cell lung cancer. J Clin Oncol. 2004; 23: 616s.
  • 9
    Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003; 21: 2237–2246.
  • 10
    Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA. 2003; 290: 2149–2158.
  • 11
    Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005; 366: 1527–1537.
  • 12
    Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497–1500.
  • 13
    Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129–2139.
  • 14
    Tsao M, Sakurada A, Cutz J, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005; 353: 133–144.
  • 15
    Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005; 23: 8081–8092.
  • 16
    Cappuzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005; 97: 643–655.
  • 17
    Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005; 23: 2513–2520.
  • 18
    Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005; 23: 6829–6837.
  • 19
    Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97: 339–346.
  • 20
    Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352: 786–792.
  • 21
    Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2: e73.
  • 22
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205–216.
  • 23
    National Cancer Institute- Common Toxicity Criteria, version 2.0: the Japan Clinical Oncology Group version. Gan To Kagaku Ryoho 1999; 26: 1084–1144.
  • 24
    Ceresoli GL, Cappuzzo F, Gregore V, Bartolini S, Crino L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective study. Ann Oncol. 2004; 15: 1042–1047.
  • 25
    Hotta K, Kiura K, Ueoka H, et al. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer. 2004; 46: 255–261.
  • 26
    Takigawa N, Segawa Y, Okahara M, et al. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer. 1996; 15: 67–77.
  • 27
    Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991; 9: 1618–1626.
  • 28
    Kantarjian H, O'Brien S, Cortes J, et al. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-α failure and in late CML-CP, comparison with historical controls. Clin Cancer Res. 2004; 10: 68–75.
  • 29
    O'Dwyer ME, Mauro MJ, Blasdel C, et al. Clonal evolution and lack of cytogenetic response and adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood. 2004; 103: 451–455.
  • 30
    Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol. 2005; 23: 5795–5804.
  • 31
    Judson I, Ma P, Peng B, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol. 2005; 55: 379–386.
  • 32
    Niho S, Kubota K, Goto K, et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 2006; 24: 64–69.
  • 33
    Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol. 2004; 22: 777–784.
  • 34
    Herbst RS, Giaccone G, Shiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol. 2004; 22: 785–794.
View Full Article (HTML) Get PDF (115K)